Travoprost

Drug Profile

Travoprost

Alternative Names: AL 06221; AL-6221; Izba; Travatan; Travatan APS; Travatan Z; Travatanz; Travoprost advanced preservative system; Travoprost APS

Latest Information Update: 24 Mar 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Alcon
  • Class Antiglaucomas; Eye disorder therapies; Prostaglandins; Small molecules
  • Mechanism of Action Prostaglandin F2 alpha agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Open-angle glaucoma
  • No development reported Ocular hypertension

Most Recent Events

  • 27 Jan 2017 Novartis has patent protection for travoprost in Europe and Japan (Novartis 20-F filed in 2017)
  • 16 Jul 2016 No recent reports of development identified for phase-I development in Ocular-hypertension(In adolescents, In children, In infants) in Saudi Arabia (Ophthalmic, Drops)
  • 24 Dec 2014 Launched for Open angle glaucoma (In adolescents, In children) in European Union, Norway, Iceland and Liechtenstein (Ophthalmic)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top